Evidence mapPaperPMID 39015555Full record

ReviewMedComm2024

Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Chuan Xu, Chaoyang Jiang, Zhihui Li, Hui Gao, Jing Xian, Wenyan Guo, Dan He, Xingchen Peng, Daijun Zhou, Dong Li

Abstract readReview
In one paragraph

Review in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Exosome-Based Liquid Biopsy in Early Screening and Diagnosis of Cancers.Dose-response : a publication of International Hormesis Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chuan XuDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Chaoyang JiangDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Zhihui LiDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Hui GaoDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Jing XianDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Wenyan GuoDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Dan HeDepartment of Oncology The Second Affiliated Hospital of Chengdu Medical College China National Nuclear Corporation 416 Hospital Chengdu Sichuan China.
Xingchen PengDepartment of Biotherapy Cancer Center West China Hospital Sichuan University Chengdu Sichuan China.ORCID https://orcid.org/0000-0001-7042-718X
Daijun ZhouDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.
Dong LiDepartment of Oncology The General Hospital of Western Theater Command Chengdu China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are nanoscale vesicles of cellular origin. One of the main characteristics of exosomes is their ability to carry a wide range of biomolecules from their parental cells, which are important mediators of intercellular communication and play an important role in physiological and pathological processes. Exosomes have the advantages of biocompatibility, low immunogenicity, and wide biodistribution. As researchers' understanding of exosomes has increased, various strategies have been proposed for their use in diagnosing and treating diseases. Here, we provide an overview of the biogenesis and composition of exosomes, describe the relationship between exosomes and disease progression, and focus on the use of exosomes as biomarkers for early screening, disease monitoring, and guiding therapy in refractory diseases such as tumors and neurodegenerative diseases. We also summarize the current applications of exosomes, especially engineered exosomes, for efficient drug delivery, targeted therapies, gene therapies, and immune vaccines. Finally, the current challenges and potential research directions for the clinical application of exosomes are also discussed. In conclusion, exosomes, as an emerging molecule that can be used in the diagnosis and treatment of diseases, combined with multidisciplinary innovative solutions, will play an important role in clinical applications.

Indexed as

drug deliveryexosomeimmunotherapyliquid biopsytargeted therapies

Identifiers

PMID39015555
PMCPMC11247338

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.